Expression profiling of circulating tumor cells

13th October

Researchers from University of Essen in collaboration with Qiagen and TATAA stratify breast cancer patients based on expression profiling of circulating tumor cells

Circulating tumor cells (CTC) are thought to be an ideal surrogate marker to monitor disease progression in metastatic breast cancer (MBC).We investigated the prediction of treatment response in CTC of MBC patients on the basis of the expression of 46 genes.

CTCs are proposed to be an attractive source of liquid biopsy markers for monitoring disease progression. CTCs are highly heterogeneous and can change in number and phenotype under anticancer treatment. Stem cell-like tumor cells, undergoing epithelial-mesenchymal-transition (EMT) and not displaying the classical epithelial phenotype, are discussed as an active source of metastatic spread and have been identified within the population of CTCs.

> Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer-Clin Chem (2017)

TATAA GrandPerformance Assays – Cancer Panel

AdnaTest platform

TATAA PreAmp GrandMaster® Mix

ValidPrime® Control for Genomic Background